Trials / Active Not Recruiting
Active Not RecruitingNCT04910022
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients With Recurrent Glioblastoma
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Nerviano Medical Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NMS-03305293 | Route of administration: Oral |
| DRUG | Temozolomide | Route of administration: Oral Commercially available temozolomide |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2027-05-30
- Completion
- 2027-09-07
- First posted
- 2021-06-02
- Last updated
- 2025-08-19
Locations
18 sites across 5 countries: United States, Italy, Netherlands, Puerto Rico, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04910022. Inclusion in this directory is not an endorsement.